A/RES/70/266 Political Declaration on HIV and AIDS: On the Fast Track to Accelerating the Fight against HIV and to Ending the AIDS Epidemic by 2030 co-location of HIV and tuberculosis services, ensuring that national protocols for HIV/tuberculosis co-infection are updated within two years to reflect the latest World Health Organization recommendations; 60 (h). Commit to reducing the high rates of HIV and hepatitis B and C co-infection and ensuring that, by 2020, efforts are made to reduce by 30 per cent new cases of chronic viral hepatitis B and C infections and to have 5 million people receiving hepatitis B treatment and to have treated 3 million people with chronic hepatitis C infection, also taking into account the linkages to and lessons learned from the AIDS response, such as the promotion and protection of human rights, the reduction of stigma and discrimination, community engagement, stronger integration of HIV and hepatitis B and C service delivery, and efforts towards guaranteeing access to affordable medicines and effective prevention interventions , particularly for vulnerable populations and populations that epidemiological evidence shows a re at higher risk of infection; 60 (i). Commit to measures to ensure access to safe, affordable and efficacious medicines, including generic medicines, diagnostics and related health technologies, utilizing all available tools to reduce the price of life -saving drugs and diagnostics, and note the establishment of the High-level Panel on Access to Medicines convened by the Secretary General; 60 (j). Recognize the critical importance of affordable medicines, including generics, in scaling up access to affordable HIV treatment, and furth er recognize that protection and enforcement measures for intellectual property rights should be compliant with the World Trade Organization Agreement on Trade -Related Aspects of Intellectual Property Rights (TRIPS Agreement) and should be interpreted and implemented in a manner supportive of the right of Member States to protect public health and, in particular, to promote access to medicines for all, and welcome the adoption by the TRIPS Council on 6 November 2015 of the decision on the extension of the transition period under article 66, paragraph 1, of the TRIPS Agreement for least-developed country members for certain obligations with respect to pharmaceutical products; 60 (k). Note with concern that regulations, policies and practices, including those that limit legitimate trade in generic medicines, may seriously limit access to affordable HIV treatment and other pharmaceutical products in low - and middleincome countries, and recognize that improvements can be made, inter alia through national legislation, regulatory policy and supply chain management, noting that reductions in barriers to affordable products could be explored in order to expand access to safe, effective, affordable and good quality HIV prevention products, diagnostics, medicine, vaccines and treatment commodities for HIV, including for opportunistic infections and co-infections; 60 (l). Commit to urgently removing, where feasible, obstacles that limit the capacity of low- and middle-income countries to provide affordable and effective HIV prevention and treatment products, diagnostics, medicines and commodities and other pharmaceutical products, as well as treatment for opportunistic infections, co-morbidities and co-infections, and to reducing costs associated with lifelong chronic care, including by amending national laws and regulations, as deemed appropriate by respective Governments, so as to optimize: (i) The use, to the full, of existing flexibilities under the Agreement on Trade-Related Aspects of Intellectual Property Rights specifically geared to promoting access to and trade in medicines, and, while recognizing the importance of the intellectual property rights regime in contributing to a 16/26